Maxime Verhoeven

47 An indirect comparison of treat-to-target strategies in early RA Table 1 Baseline characteristics. U-Act-Early n= 317 CAMERA-II n= 236 P-value Female, n (%) 212 (67) 142 (60) 0.11 Age (yrs.), mean (SD) 53.4 (12.8) 53.7 (13.4) 0.79 BMI (mg/kg²), mean (SD) 26.2 (4.3) 25.8 (4.0) 0.23 Alcohol use (≥1 unit/week), n (%) 192 (61) 84 (40) <0.01 Current smoker, n (%) 90 (28) 69 (32) 0.34 Education level, n (%) Low Moderate High 136 (46) 112 (38) 48 (16) 77 (46) 53 (31) 38 (23) 0.35 Disease duration (days), median (IQR) 26 (16 - 43) * RF-positive status, n (%) 231 (73) 118 (60) <0.01 DAS28, mean (SD) 5.2 (1.1) 5.7 (1.3) <0.01 CRP (mg/L), median (IQR) 9.0 (3.0 – 21.0) 17.0 (0.0 – 44.0) 0.06 ESR (mm per h), median (IQR) 25.0 (14.0 – 44.0) 31.0 (16.0 – 48.0) 0.02 SJC28, median (IQR) 6.0 (3.0 – 11.0) 10.0 (6.0 – 15.0) <0.01 TJC28, median (IQR) 7.0 (4.0 – 11.0) 9.0 (5.5 – 16.0) <0.01 HAQ score, median (IQR) 1.1 (0.6 – 1.5) 1.1 (0.6 – 1.5) 0.52 Any radiographic joint damage, n (%) 83 (26) 57 (24) 0.62 Outcomes are based on non-imputed data of the 2 trials. Reported baseline characteristics of CAMERA- II slightly differ from those of the original publication as we presented non-imputed data compared to imputed data in that publication. 6,12 * not collected, but at least <1 year according to the inclusion criteria. SD= standard deviation; BMI= body mass index; RF= rheumatoid factor; DAS28= disease activity score assessing 28 joints [range 0-9.4; higher is more activity]; CRP= C-reactive protein in milligram per litre; IQR= interquartile range; ESR= erythrocyte sedimentation rate in millimetre per hour; SJC28= 28 swollen joint count; TJC28= 28 tender joint count; HAQ= health assessment questionnaire [range 0-3, 3= worst function]; any radiographic joint damage= total Sharp van der Heijde score ≥1. The average DAS28 over 24 months was statistically significantly lower in the TCZ+MTX arm compared to the MTX+Pred arm (-0.62 [95%CI -1.14 to -0.10]), Table 2 and Figure 1a. The analyses using the m-CDAI over 24 months as outcome showed no significant differences, but over the first 3 months significantly higher disease activity for TCZ arms compared to the MTX+Pred is found, Table 2 and Figure 1b. DAS28 remission over 24 months was statistically significantly more often achieved in the TCZ arms compared to the MTX+Pred arm (TCZ+MTX: relative risk (RR) 1.11 [95%CI 1.02 to 1.22]; TCZ: RR 1.09 [95%CI 1.00 to 1.20]), as well over the first 3 months (TCZ+MTX: RR 1.12 [95%CI 1.02 to 1.22]; TCZ: RR 1.11 [95%CI 1.01 to 1.22]), Table 2 and Supplementary Figure S1a. M-CDAI remission was statistically significantly more often achieved in the MTX+Pred arm compared to the TCZ arms over the first 3 months (RR: TCZ+MTX vs. MTX+Pred: 0.90 [95%CI 0.81 to 0.99]; TCZ vs. MTX+Pred: 0.88 [95%CI 0.89 3